Hallym Meropenem Injection 500 mg (Meropenem Hydrate)

Adult administration

As meropenem hydrate, administer 0.5 to 1 g (potency) divided into 2 to 3 doses daily via intravenous infusion over 30 minutes. For suspected infections in pneumonia, peritonitis, and neutropenic patients, 1 g (potency) is administered every 8 hours via intravenous infusion. For cystic fibrosis and meningitis, administer 2 g (potency) every 8 hours via intravenous infusion.

Child administration

For bacterial meningitis in children over 3 months, through intravenous infusion over 30 minutes, administer 40 mg per kg of body weight every 8 hours according to the pathogen's susceptibility and the patient's condition.

This drug should not be used in patients with a history of allergic reactions or shock. Special caution is required for patients currently taking Valproate sodium, as this medication may lower the blood concentration of valproate, increasing the risk of seizure recurrence. Additionally, patients who have shown hypersensitivity to this drug or its components, or have experienced severe allergic reactions to other carbapenems or beta-lactam antibiotics should avoid administration. This drug should be administered with caution to patients with a history of allergies or those with compromised renal function, a history of epilepsy, severely impaired liver function, the elderly, infants, and others requiring special attention. In particular, if renal function is impaired, dosage adjustments should be made, and signs of central nervous system symptoms should be closely monitored. This drug can cause a variety of side effects including shock, rash, urticaria, severe swelling (angioedema), chest tightness, difficulty breathing, sweating, pallor, severe allergic reactions, severe rashes with high fever, blistering, skin peeling, oral/ocular mucosal pain, severe skin reactions, asthma, respiratory issues combined with cough and fever, shortness of breath or difficulty breathing, respiratory issues, jaundice of skin or eyes, systemic lethargy, liver abnormalities, sudden and severe adverse events, and other effects; therefore, patients should be monitored closely during treatment. If any abnormal symptoms occur, administration should be halted immediately, and appropriate treatment must be sought. To prevent the development of resistant strains, this drug should only be used for the minimum required duration after susceptibility testing. Long-term use requires regular monitoring, including liver function tests. Additionally, it is imperative to confirm whether the patient has a history of hypersensitivity to beta-lactam drugs. Caution is necessary when driving or operating machinery, as headache and alterations in mental state may occur. Symptoms of rhabdomyolysis such as myalgia, muscle weakness, and dark-colored urine should lead to immediate cessation of the drug. This drug may interact with other medications. Special consultation and careful monitoring of blood concentration and effects are required when used in conjunction with probenecid, valproate, antiepileptic drugs, hormonal contraceptives, warfarin, and others. For women who are pregnant or may become pregnant, this drug should only be administered when the benefits outweigh the risks. It is also advisable to avoid use during breastfeeding. Safety in infants under 3 months has not been established, thus caution is required. This medication should be used rapidly following dissolution and can only be administered via intravenous injection. When utilizing this drug, continuously observe the patient's condition and alert medical personnel immediately if any adverse reactions arise.

Serious side effects

Shock, anaphylaxis, urticaria, severe swelling (angioedema), chest tightness, difficulty breathing, cold sweat, pallor, severe allergic reaction, severe rash with high fever, blistering, skin peeling, oral/ocular mucosal pain, severe adverse skin reactions, asthma, respiratory issues accompanied by cough and fever, shortness of breath or difficulty breathing, respiratory issues, jaundice of skin or eyes, systemic lethargy, liver abnormalities, sudden and severe adverse events,

Mild side effects

• Dizziness
• diarrhea
• tinnitus
• sweating
• rash
• feverishness
• erythema
• itching
• fever
• redness

This medication should be stored in a sealed container and kept at room temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the drug's effectiveness.

Appearance

A white to pale yellow crystalline powder contained in a colorless and transparent vial for injection.

Package unit

10 vials (604 mg/vial x 10)